BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1015 related articles for article (PubMed ID: 25877329)

  • 1. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.
    Ratner N; Miller SJ
    Nat Rev Cancer; 2015 May; 15(5):290-301. PubMed ID: 25877329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The NF1 gene in tumor syndromes and melanoma.
    Kiuru M; Busam KJ
    Lab Invest; 2017 Feb; 97(2):146-157. PubMed ID: 28067895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
    Gottfried ON; Viskochil DH; Couldwell WT
    Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurofibromatosis 1: closing the GAP between mice and men.
    Dasgupta B; Gutmann DH
    Curr Opin Genet Dev; 2003 Feb; 13(1):20-7. PubMed ID: 12573431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurofibromatosis type 1: Fundamental insights into cell signalling and cancer.
    Rad E; Tee AR
    Semin Cell Dev Biol; 2016 Apr; 52():39-46. PubMed ID: 26860753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular genetics of neurofibromatosis type 1].
    Suzuki H; Takahashi K; Shibahara S
    Nihon Rinsho; 1993 Sep; 51(9):2457-61. PubMed ID: 8411728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease.
    Abramowicz A; Gos M
    Dev Period Med; 2014; 18(3):297-306. PubMed ID: 25182393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.
    Dilworth JT; Kraniak JM; Wojtkowiak JW; Gibbs RA; Borch RF; Tainsky MA; Reiners JJ; Mattingly RR
    Biochem Pharmacol; 2006 Nov; 72(11):1485-92. PubMed ID: 16797490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurofibromatosis type 1 peripheral nerve tumors: aberrant activation of the Ras pathway.
    Feldkamp MM; Angelov L; Guha A
    Surg Neurol; 1999 Feb; 51(2):211-8. PubMed ID: 10029430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The NF1 somatic mutational landscape in sporadic human cancers.
    Philpott C; Tovell H; Frayling IM; Cooper DN; Upadhyaya M
    Hum Genomics; 2017 Jun; 11(1):13. PubMed ID: 28637487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatic mutations in the neurofibromatosis 1 gene in human tumors.
    Li Y; Bollag G; Clark R; Stevens J; Conroy L; Fults D; Ward K; Friedman E; Samowitz W; Robertson M
    Cell; 1992 Apr; 69(2):275-81. PubMed ID: 1568247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel diagnostic method to detect truncated neurofibromin in neurofibromatosis 1.
    Esposito T; Piluso G; Saracino D; Uccello R; Schettino C; Dato C; Capaldo G; Giugliano T; Varriale B; Paolisso G; Di Iorio G; Melone MA
    J Neurochem; 2015 Dec; 135(6):1123-8. PubMed ID: 26478990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The promise of signal transduction in genetically driven sarcomas of the nerve.
    Kim A; Pratilas CA
    Exp Neurol; 2018 Jan; 299(Pt B):317-325. PubMed ID: 28859862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The genetic and molecular pathogenesis of NF1 and NF2.
    Yohay KH
    Semin Pediatr Neurol; 2006 Mar; 13(1):21-6. PubMed ID: 16818172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurofibromatosis type 1 (NF1) gene: Beyond café au lait spots and dermal neurofibromas.
    Peltonen S; Kallionpää RA; Peltonen J
    Exp Dermatol; 2017 Jul; 26(7):645-648. PubMed ID: 27622733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphomas in patients with neurofibromatosis type 1 (NF1): another malignancy in the NF1 syndrome?
    Fareez F; Wang BH; Brain I; Lu JQ
    Pathology; 2023 Apr; 55(3):302-314. PubMed ID: 36774237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel and Recurring Disease-Causing NF1 Variants in Two Chinese Families with Neurofibromatosis Type 1.
    Xiao H; Yuan L; Xu H; Yang Z; Huang F; Song Z; Yang Y; Zeng C; Deng H
    J Mol Neurosci; 2018 Aug; 65(4):557-563. PubMed ID: 30046999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1.
    Klose A; Ahmadian MR; Schuelke M; Scheffzek K; Hoffmeyer S; Gewies A; Schmitz F; Kaufmann D; Peters H; Wittinghofer A; Nürnberg P
    Hum Mol Genet; 1998 Aug; 7(8):1261-8. PubMed ID: 9668168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.
    Witkowski L; Dillon MW; Murphy E; S Lebo M; Mason-Suares H
    Mol Genet Genomic Med; 2020 Apr; 8(4):e1180. PubMed ID: 32107864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes.
    Dasgupta B; Dugan LL; Gutmann DH
    J Neurosci; 2003 Oct; 23(26):8949-54. PubMed ID: 14523097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.